PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds, announced today that its research and development team has finalized a unique proprietary formulation with antimicrobial claims that allows for immediate marketing of this product in the United States within a specific medical market without the need for pre-approval by the FDA.
